FY2016 EPS Estimates for Illumina Inc. (ILMN) Reduced by Analyst
Illumina Inc. (NASDAQ:ILMN) – Investment analysts at First Analysis lowered their FY2016 EPS estimates for shares of Illumina in a research note issued on Tuesday. First Analysis analyst T. Marshbanks now expects that the firm will post earnings of $3.34 per share for the year, down from their prior forecast of $3.51. First Analysis also issued estimates for Illumina’s Q4 2016 earnings at $0.92 EPS, Q1 2017 earnings at $0.79 EPS and FY2017 earnings at $3.58 EPS.
ILMN has been the topic of a number of other research reports. Zacks Investment Research raised Illumina from a “sell” rating to a “hold” rating in a research note on Monday, July 4th. CL King cut Illumina from a “buy” rating to a “neutral” rating in a research note on Monday, August 22nd. Piper Jaffray Cos. reissued an “overweight” rating and issued a $161.00 price target on shares of Illumina in a research note on Friday, July 15th. Wells Fargo & Co. reissued a “market perform” rating and issued a $137.50 price target (down previously from $150.00) on shares of Illumina in a research note on Wednesday. Finally, Vetr raised Illumina from a “sell” rating to a “buy” rating and set a $198.61 price target on the stock in a research note on Monday, October 3rd. Two analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. Illumina presently has an average rating of “Hold” and an average target price of $157.50.
Shares of Illumina (NASDAQ:ILMN) traded up 0.2870% on Thursday, hitting $136.5708. 1,141,348 shares of the stock traded hands. The company’s 50 day moving average is $172.97 and its 200 day moving average is $156.29. The stock has a market cap of $20.02 billion, a price-to-earnings ratio of 46.7708 and a beta of 0.47. Illumina has a one year low of $127.10 and a one year high of $196.47.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/13/fy2016-eps-estimates-for-illumina-inc-ilmn-reduced-by-analyst.html
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, July 26th. The life sciences company reported $0.86 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.13. The business had revenue of $600 million for the quarter, compared to analyst estimates of $31.91 million. Illumina had a net margin of 18.73% and a return on equity of 23.69%. The company’s revenue was up 11.3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.80 EPS.
In other news, SVP Charles Dadswell sold 8,632 shares of the stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $155.00, for a total transaction of $1,337,960.00. Following the sale, the senior vice president now owns 40,248 shares in the company, valued at $6,238,440. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Marc Stapley sold 1,270 shares of the stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $172.87, for a total value of $219,544.90. Following the sale, the executive vice president now owns 33,916 shares in the company, valued at approximately $5,863,058.92. The disclosure for this sale can be found here. 1.60% of the stock is owned by company insiders.
Several hedge funds have recently made changes to their positions in ILMN. Baillie Gifford & Co. boosted its stake in shares of Illumina by 3.8% in the second quarter. Baillie Gifford & Co. now owns 18,615,061 shares of the life sciences company’s stock valued at $2,613,182,000 after buying an additional 682,010 shares during the last quarter. Capital Research Global Investors boosted its stake in shares of Illumina by 17.1% in the second quarter. Capital Research Global Investors now owns 13,085,071 shares of the life sciences company’s stock valued at $1,836,882,000 after buying an additional 1,910,346 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Illumina by 2.0% in the second quarter. Vanguard Group Inc. now owns 8,982,784 shares of the life sciences company’s stock valued at $1,261,004,000 after buying an additional 178,186 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its stake in shares of Illumina by 1.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 3,835,363 shares of the life sciences company’s stock valued at $538,408,000 after buying an additional 43,515 shares during the last quarter. Finally, Capital World Investors boosted its stake in shares of Illumina by 218.0% in the second quarter. Capital World Investors now owns 1,463,000 shares of the life sciences company’s stock valued at $205,376,000 after buying an additional 1,003,000 shares during the last quarter. Institutional investors own 95.22% of the company’s stock.
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.